First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 564 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or... March 18, 2025 Can Age Affect Response to Immune Checkpoint Inhibitors? July 6, 2018 Spotlight On: Occupational Therapists in Cancer Care November 4, 2021 20 years of Cancer Research UK: Celebrating our research nurses December 7, 2022 Load more HOT NEWS Immune Responses Similar for Adjuvanted and Standard Dose Influenza Vaccines for... 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Genitourinary... Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab Kids Facing Difficult Medical Diagnoses Take Train To The ‘North Pole’...
